Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase

Randal W. Berg, Melanie Werner, Peter J. Ferguson, Carl Postenka, Mark Vincent, D. James Koropatnick and Elke Behrend
Journal of Pharmacology and Experimental Therapeutics August 2001, 298 (2) 477-484;
Randal W. Berg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Werner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Ferguson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Postenka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. James Koropatnick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elke Behrend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Chemotherapeutic agents targeting thymidylate synthase (TS) are effective against human tumors. Efficacy is limited by drug resistance, often mediated by TS overexpression. Treatment of HeLa cells in vitro with an antisense oligodeoxynucleotide (ODN 83) targeting human TS mRNA reduces TS mRNA and protein levels, inhibits cell proliferation, and sensitizes cells to TS-targeting drugs (Ferguson et al., 1999). The present study investigates the mechanism by which ODN 83 inhibits cell proliferation and examines its antitumor efficacy in vivo. ODN 83 treatment did not induce apoptosis in HeLa cells in vitro but caused accumulation of cells at G2/M. In contrast, TS-targeting chemotherapeutics arrest at G1 or S. Antisense down-regulation reduced TS mRNA levels in human colon cancer (HT29) cells by 40% in vitro, resulted in G2/M arrest, and reduced proliferation without enhanced cell death. Growth of HT29 tumors in immunocompromised mice was significantly inhibited when antisense ODN 83 treatment began promptly after tumor implantation and was accompanied by a 40% reduction in TS protein levels. Growth of tumors allowed to reach 400 mm3 prior to ODN administration was unaffected by antisense ODN 83. Radiolabeled ODNs were localized to the tumor periphery but evenly distributed in normal tissue. Thus, down-regulation of TS mRNA and protein by antisense ODN treatment exerts a novel G2/M cell cycle block without increasing cell death and inhibits HT29 tumor cell growth in vivo. Antisense ODN 83 may be an effective therapy for colon carcinoma, alone or in combination with TS-targeting cytotoxic drugs.

Footnotes

  • This work was supported by funds awarded to M.V. and J.K. by Zeneca Pharma Canada, Ltd., and Imperial Oil, Ltd.

  • Abbreviations:
    TS
    thymidylate synthase
    ODN
    oligodeoxynucleotide
    5-FU
    5-fluorouracil
    5-FUdR
    5-fluorodeoxyuridine
    5-FdUMP
    5-fluorodeoxyuridine monophosphate
    RT-PCR
    reverse transcriptase-polymerase chain reaction
    GAPDH
    glyceraldehyde-3-phosphate dehydrogenase
    • Received February 15, 2001.
    • Accepted April 18, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 298 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 298, Issue 2
1 Aug 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase

Randal W. Berg, Melanie Werner, Peter J. Ferguson, Carl Postenka, Mark Vincent, D. James Koropatnick and Elke Behrend
Journal of Pharmacology and Experimental Therapeutics August 1, 2001, 298 (2) 477-484;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase

Randal W. Berg, Melanie Werner, Peter J. Ferguson, Carl Postenka, Mark Vincent, D. James Koropatnick and Elke Behrend
Journal of Pharmacology and Experimental Therapeutics August 1, 2001, 298 (2) 477-484;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • miR-9-3p and -5p Mediate Drug Resistance by Targeting TOP2β
  • Ocular Palonosetron for Prevention of Nausea and Vomiting
  • PTP4A3 and ovarian cancer
Show more Chemotherapy, Antibiotics, and Gene Therapy

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics